HCW Biologics .
Developing transformative fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia.
About
HCW Biologics is a biotechnology company focused on developing novel fusion protein therapeutics. Their platform aims to create revolutionary treatments for a range of challenging diseases, including autoimmune disorders, cancer, and conditions associated with aging like senescence-associated dysplasia. Teams look it up for Biotech, Drug Discovery, Immunotherapy.
Frequently asked
What does HCW Biologics . do?
HCW Biologics . is a Biotech company that offers Biotech. Teams look it up for Drug Discovery, Immunotherapy, Autoimmune Diseases. It is based in Miramar, United States and was founded in 2017. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
Where is HCW Biologics . headquartered?
HCW Biologics . is headquartered in Miramar, United States.
When was HCW Biologics . founded?
HCW Biologics . was founded in 2017.
What industry does HCW Biologics . operate in?
HCW Biologics . operates in Biotech, Drug Discovery, Immunotherapy, Autoimmune Diseases, Cancer.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
“This filing concerns the resale of up to 5.7M shares of common stock by selling stockholders. The company is a clinical-stage biopharmaceutical firm developing fusion immunotherapeutics.”
View on Reddit“HCW Biologics registered shares for resale from a $4.0 million private placement, which included $600,000 from insiders, providing crucial capital amidst financial distress and Nasdaq compliance issues, though it comes with significant pote…”
View on Reddit“HCW Biologics Inc. received an extension from Nasdaq to regain compliance with the minimum $1 bid price rule, requiring demonstration by July 29, 2026, subject to conditions including a potential one-year Panel Monitor.”
View on Reddit“HCW Biologics CEO Hing C. Wong purchased $160,000 of company stock in a private placement, signaling strong conviction despite recent financial challenges and a pending dilutive offering.”
View on Reddit“HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.